Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $93.50 Consensus Price Target from Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $93.50.

A number of research firms recently weighed in on RARE. Wells Fargo & Company boosted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, December 20th. JPMorgan Chase & Co. lowered their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Finally, Wedbush restated a "neutral" rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th.

Insider Activity

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the transaction, the chief executive officer now directly owns 2,195,712 shares of the company's stock, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares of the company's stock, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,990 shares of company stock valued at $1,037,092. Company insiders own 5.80% of the company's stock.

Remove Ads

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $35,000. Human Investing LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter worth about $42,000. True Wealth Design LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $43,000. Finally, Van ECK Associates Corp increased its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded down $1.71 during midday trading on Friday, reaching $41.22. The company had a trading volume of 426,712 shares, compared to its average volume of 854,949. The firm has a 50-day moving average price of $42.91 and a 200-day moving average price of $49.10. The company has a market capitalization of $3.81 billion, a P/E ratio of -6.52 and a beta of 0.60. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. On average, equities analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.